-
The Street's Feuerstein Breaks Down Sarepta's 40% Plunge
Thursday, April 21, 2016 - 10:51am | 338Read More...Shares of Sarepta Therapeutics Inc (NASDAQ: SRPT) plunged more than 40 percent on Thursday after the U.S. Food and Drug Administration released briefing documents which consisted of an updated clinical review of the company's Duchenne muscular dystrophy drug, eteplirsen. According to The...
-
Clovis Oncology Falls 8%: Here's What You Need To Know
Friday, April 8, 2016 - 2:11pm | 320Read More...Shares of Clovis Oncology Inc (NASDAQ: CLVS) lost more than 8 percent on Friday after the company confirmed that the FDA posted briefing documents ahead of the Oncologic Drugs Advisory Committee (ODAC) meeting to discuss accelerated approval of the New Drug Application (NDA) for rociletinib. The...
-
Intercept Pharma Investors Cheering FDA Briefing Doc Release
Tuesday, April 5, 2016 - 10:03am | 337Read More...Shares of Intercept Pharmaceuticals Inc (NASDAQ: ICPT) were trading higher by more than 6 percent ahead of Tuesday's market open as investors found the U.S. Food and Drug Administration's latest briefing documents to be encouraging. The FDA has a scheduled advisory committee meeting on Thursday and...
